U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung ...

Cizzle Bio, Inc., a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Thanks to federally funded cancer research and clinical trials at Johns Hopkins, John Ryan has been able to attend ...

Radiation therapy can treat lung cancer at all stages, easing symptoms, improving precision and minimizing side effects with ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

Ankit Bharat, MD, can still remember Cornelia Tischmacher stopping their first telehealth conversation every few words to ...

TOPEKA, Kan. (WIBW) - A major advancement in lung cancer detection has arrived in Topeka.

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

The first patient has received treatment with mavrostobart plus chemo in the phase 1/2 MORNINGSTAR trial for advanced solid ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.